Press Releases

Press Releases

Date Title
04/12/19 Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection,
04/09/19 Vaxart Announces Pricing of Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 9, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public
03/28/19 Vaxart to Present at Global Medical Meetings in April
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in
03/27/19 Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 27, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the
03/20/19 Vaxart Announces Closing of Registered Direct Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 20, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of
03/19/19 Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive
03/19/19 Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
- First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18 - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by
02/06/19 Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial